Imunon (IMNN) Non-Current Assets (2010 - 2026)
Imunon's (IMNN) quarterly Non-Current Assets came in at $1.4 million in Q1 2026, down 21.03% YoY from $1.8 million in Q1 2025, and down 10.65% on a QoQ basis from $1.6 million in Q4 2025.
Imunon (IMNN) Non-Current Assets (2010 - 2026) Analysis & Trends
Imunon (IMNN) has 17 years of Non-Current Assets data on file, last reported at $1.4 million in Q1 2026.
- Quarterly Non-Current Assets fell 21.03% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.6 million (down 15.02% YoY) and the FY2025 annual result came in at $1.6 million, down 8.43% from the prior year.
- Non-Current Assets fell to $1.4 million in Q1 2026, from $1.6 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $20.5 million in Q1 2022 to a low of $1.4 million in Q1 2026.
- A 5-year average of $6.1 million and a median of $2.1 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets climbed 21.93% — and 2023, when it plunged 90.25%.
- Tracing IMNN's Non-Current Assets over 5 years: stood at $7.2 million in 2022, then slumped by 48.9% to $3.7 million in 2023, then plunged by 53.54% to $1.7 million in 2024, then dropped by 8.43% to $1.6 million in 2025, then fell by 10.65% to $1.4 million in 2026.
- The last three Non-Current Assets figures came in at $1.4 million (Q1 2026), $1.6 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Imunon | 8.42 Mn | 8.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.40 Mn |
| Dec 31, 2025 | 1.56 Mn |
| Sep 30, 2025 | 1.73 Mn |
| Jun 30, 2025 | 1.90 Mn |
| Mar 31, 2025 | 1.77 Mn |
| Dec 31, 2024 | 1.71 Mn |
| Jun 30, 2024 | 2.05 Mn |
| Mar 31, 2024 | 2.23 Mn |
| Dec 31, 2023 | 3.68 Mn |
| Sep 30, 2023 | 2.93 Mn |
| Jun 30, 2023 | 1.99 Mn |
| Mar 31, 2023 | 5.77 Mn |
| Dec 31, 2022 | 7.20 Mn |
| Sep 30, 2022 | 20.34 Mn |
| Jun 30, 2022 | 20.42 Mn |
| Mar 31, 2022 | 20.47 Mn |
| Dec 31, 2021 | 22.10 Mn |
| Sep 30, 2021 | 22.70 Mn |
| Jun 30, 2021 | 22.70 Mn |
| Mar 31, 2021 | 16.79 Mn |